Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.63 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.56 |
| ▸ | FGFR4 | P22455 | 9/20 | 0.56 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | NSD2 | O96028 | 1/20 | 0.48 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | PI4KA | P42356 | 1/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.48 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5456446 | 0.86 | HDAC6 (0.62) | HDAC6FGFR1FGFR4ADORA2API4KA | |
| SCHEMBL6659705 | 0.84 | HDAC6 (0.62) | HDAC6FGFR1FGFR4ADORA2API4KA | |
| SCHEMBL5458680 | 0.83 | HDAC6 (0.56) | HDAC6FGFR1FGFR4HDAC4HDAC1 | |
| SCHEMBL15921464 | 0.82 | ADORA2A (0.52) | HDAC6NR3C1HDAC4HDAC1ADORA2A | |
| SCHEMBL5453774 | 0.81 | HDAC6 (0.62) | HDAC6FGFR1FGFR4ADORA2API4KA | |
| SCHEMBL30984022 | 0.81 | ADORA2A (0.70) | HDAC6FGFR1FGFR4ADORA2API4KA | |
| SCHEMBL2980291 | 0.81 | ADORA2A (0.70) | HDAC6FGFR1FGFR4ADORA2API4KA | |
| SCHEMBL5458877 | 0.79 | HDAC6 (0.60) | HDAC6FGFR1FGFR4ADORA2API4KA | |
| SCHEMBL23977294 | 0.78 | HDAC6 (0.58) | HDAC6FGFR1FGFR4ADORA2API4KA | |
| SCHEMBL5467542 | 0.78 | FGFR1 (0.59) | HDAC6FGFR1FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203159-A1 | Purine compounds | UNIVERSITETET I OLSO (NO) | 2007-08-30 | — | — | US | disclosed |
| US-20070015750-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | BAEURLE STEFAN | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203159-A1 | Purine compounds | PNP, UMPS, TYMP | HDAC6 4066/4885FGFR1 3760/4885FGFR4 3148/4885 |
| US-20070015750-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | DHPS, TNF, PTGES | HDAC6 1242/4885FGFR1 2806/4885FGFR4 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.